Navigation Links
Calming fear during sleep
Date:9/22/2013

CHICAGO --- A fear memory was reduced in people by exposing them to the memory over and over again while they slept. It's the first time that emotional memory has been manipulated in humans during sleep, report Northwestern Medicine scientists.

The finding potentially offers a new way to enhance the typical daytime treatment of phobias through exposure therapy by adding a nighttime component. Exposure therapy is a common treatment for phobia and involves a gradual exposure to the feared object or situation until the fear is extinguished.

"It's a novel finding," said Katherina Hauner, a postdoctoral fellow in neurology at Northwestern University Feinberg School of Medicine. "We showed a small but significant decrease in fear. If it can be extended to pre-existing fear, the bigger picture is that, perhaps, the treatment of phobias can be enhanced during sleep."

Hauner did the research in the lab of Jay Gottfried, associate professor of neurology at Feinberg and senior author of the paper.

The study will be published Sept. 22 in the journal Nature Neuroscience.

Previous projects have shown that spatial learning and motor sequence learning can be enhanced during sleep. It wasn't previously known that emotions could be manipulated during sleep, Northwestern investigators said.

In the study, 15 healthy human subjects received mild electric shocks while seeing two different faces. They also smelled a specific odorant while viewing each face and being shocked, so the face and the odorant both were associated with fear. Subjects received different odorants to smell with each face such as woody, clove, new sneaker, lemon or mint.

Then, when a subject was asleep, one of the two odorants was re-presented, but in the absence of the associated faces and shocks. This occurred during slow wave sleep when memory consolidation is thought to occur. Sleep is very important for strengthening new memories, noted Hauner, also a research scientist at the Rehabilitation Institute of Chicago.

"While this particular odorant was being presented during sleep, it was reactivating the memory of that face over and over again which is similar to the process of fear extinction during exposure therapy," Hauner said.

When the subjects woke up, they were exposed to both faces. When they saw the face linked to the smell they had been exposed to during sleep, their fear reactions were lower than their fear reactions to the other face.

Fear was measured in two ways: through small amounts of sweat in the skin, similar to a lie detector test, and through neuroimaging with fMRI (functional magnetic resonance imaging). The fMRI results showed changes in regions associated with memory, such as the hippocampus, and changes in patterns of brain activity in regions associated with emotion, such as the amygdala. These brain changes reflected a decrease in reactivity that was specific to the targeted face image associated with the odorant presented during sleep.


'/>"/>

Contact: Marla Paul
Marla-Paul@northwestern.edu
312-503-8928
Northwestern University
Source:Eurekalert

Related medicine news :

1. Android Phone Owners Can Now Get Instant Calming Relief from Panic Attacks with New Panic Attack Aid App
2. New Kid-Friendly “Happy Visits” and Calming Nitrous are Being Implemented by Stonehaven Family Dentist of Salt Lake City
3. Exercise improves quality of life during breast cancer treatment
4. Presidential Recognition Awards presented during the 2012 AIUM Annual Convention
5. Heroin Addicts Have Higher Pain Sensitivity, Even During Treatment
6. HIV Drug Tenofovir Safe During Pregnancy, Study Suggests
7. Breathing during radiotherapy - how to hit the treatment target without causing collateral damage
8. To avoid pain during an injection, look away
9. AGA presents cutting-edge research during DDW®
10. Troublesome dyspnea during sexual activity is common in COPD patients
11. Flu shot during pregnancy shows unexpected benefits in large study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... , ... April 26, 2017 , ... RawTrition now brings ... way to get nutrients from SUPERFOODS! , RawTrition is taking nutrients to ... cellular level because the body recognizes its raw form (unlike the synthetically made options ...
(Date:4/26/2017)... ... April 26, 2017 , ... MYOLYN, ... to announce that it has received 510(k) clearance from the U.S. Food & ... the MyoCycle Pro. , Both devices are stationary cycling systems that use MYOLYN’s ...
(Date:4/25/2017)... ... April 25, 2017 , ... Coalition Duchenne, ... Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor Therapeutics on ... clinical trial in Duchenne announced today. , Coalition Duchenne funded studies carried ...
(Date:4/25/2017)... ... ... The doctors at Wall Centre Dental are now expanding their practice by accepting ... receive dental care. The doctors offer three treatment options to put victims of ... at their dental office in Vancouver. Wall Centre Dental is currently welcoming even patients ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... unveiling cutting-edge birth defects research related to Zika virus during pregnancy, as well ... society for this important science. , The Teratology Society is ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... 20, 2017  CVS Pharmacy, the retail division ... new store design to enhance the retail customer ... health-focused products and expanded beauty selections paired with ... discover new offerings. Together with its innovative digital ... the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
Breaking Medicine Technology: